Original Article

You have full text access to this OnlineOpen article

Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy

  1. Masatoshi Inagaki MD, PhD1,
  2. Eisho Yoshikawa MD, PhD2,
  3. Yutaka Matsuoka MD, PhD3,
  4. Yuriko Sugawara MD, PhD4,
  5. Tomohito Nakano MD5,
  6. Tatsuo Akechi MD, PhD6,
  7. Noriaki Wada MD7,
  8. Shigeru Imoto MD, PhD7,
  9. Koji Murakami MD, PhD8,
  10. Yosuke Uchitomi MD, PhD1,†,*,
  11. and The Breast Cancer Survivors' Brain MRI Database Group‡

Article first published online: 27 NOV 2006

DOI: 10.1002/cncr.22368

Issue

Cancer

Cancer

Volume 109, Issue 1, pages 146–156, 1 January 2007

Additional Information

How to Cite

Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., Wada, N., Imoto, S., Murakami, K., Uchitomi, Y. and and The Breast Cancer Survivors' Brain MRI Database Group (2007), Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109: 146–156. doi: 10.1002/cncr.22368

Author Information

  1. 1

    Psycho-Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan

  2. 2

    Division of Psycho-Oncology, Shizuoka Cancer Center, Shizuoka, Japan

  3. 3

    Division of Adult Mental Health, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

  4. 4

    Department of Psychiatry and Behavioral Science, Tokai University School of Medicine, Kanagawa, Japan

  5. 5

    Department of Psychiatry, Kitasato Institute Hospital, Tokyo, Japan

  6. 6

    Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  7. 7

    Division of Breast Surgery, National Cancer Center Hospital East, Chiba, Japan

  8. 8

    PET Center, Dokkyo University School of Medicine, Tochigi, Japan

  1. †

    Fax: (011) 81-4-7134-7026.

  2. ‡

    The members of the Breast Cancer Survivors' Brain MRI Database Group are Makoto Kobayakawa, MD (Department of Psychiatry, Hiroshima University Hospital, Hiroshima, Japan); Nobuya Akizuki, MD, PhD, and Maiko Fujimori, PhD (Psycho-Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan); in addition to the authors listed above. All members of the group are authors of the current study and meet criteria for authorship.

*Psycho-Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577 Japan

Publication History

  1. Issue published online: 11 DEC 2006
  2. Article first published online: 27 NOV 2006
  3. Manuscript Accepted: 6 OCT 2006
  4. Manuscript Revised: 4 OCT 2006
  5. Manuscript Received: 6 SEP 2006

Funded by

  • Japanese Ministry of Health, Labor, and Welfare
  • Japan Society for the Promotion of Science
  • Japanese Ministry of Education, Culture, Science, and Technology
  • Foundation for Promotion of Cancer Research in Japan

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (417K)

REFERENCES

  • 1
    Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst. 2003; 95: 190–197.
  • 2
    Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004; 101: 466–475.
    Direct Link:
  • 3
    Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005; 104: 2222–2233.
    Direct Link:
  • 4
    Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005; 59: 60–70.
  • 5
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967–982.
  • 6
    Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005; 12: 279–287.
  • 7
    Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994; 20: 191–214.
  • 8
    Troy L, McFarland K, Littman-Power S, et al. Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology. 2000; 9: 29–39.
  • 9
    Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001; 16: 328–334.
  • 10
    Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry. 2003; 8: 201–216.
  • 11
    Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003; 30: 749–762.
  • 12
    Madhyastha S, Somayaji SN, Rao MS, Nalini K, Bairy KL. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol. 2002; 80: 1076–1084.
  • 13
    van der Kooy D, Zito KA, Roberts DC. Evidence on the retrograde neurotoxicity of doxorubicin. Neurosci Lett. 1985; 53: 215–219.
  • 14
    Rzeski W, Pruskil S, Macke A, et al. Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol. 2004; 56: 351–360.
    Direct Link:
  • 15
    Joshi G, Sultana R, Tangpong J, et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res. 2005; 39: 1147–1154.
  • 16
    Yoshikawa E, Matsuoka Y, Inagaki M, et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat. 2005; 92: 81–84.
  • 17
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485–493.
  • 18
    Fan HG, Houede-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005; 23: 8025–8032.
  • 19
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13: 1387–1397.
  • 20
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 2292–2299.
    Direct Link:
  • 21
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189–198.
  • 22
    Mori E, Mitani Y, Yamadori A. [ Usefulness of a Japanese version of the Mini-Mental State in neurological patients]. (Japanese). Shinkeishinrigaku. 1985; 1: 82–90.
  • 23
    Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000; 57: 925–935.
  • 24
    Wechsler D. Wechsler Memory Scale-Revised. New York: Psychological Corp; 1987.
  • 25
    Sugishita M. Wechsler Memory Scale-Revised (Japanese). Tokyo: Nihonbunkakagakusya; 2001.
  • 26
    Omura K, Sugishita M. Simultaneous confirmatory factor analysis of the Wechsler memory scale – revised for two standardization samples: a comparison of groups from Japan and the United States. J Clin Exp Neuropsychol. 2004; 26: 645–652.
  • 27
    Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage. 2000; 11(6 pt 1): 805–821.
  • 28
    Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001; 14(1 pt 1): 21–36.
  • 29
    Good CD, Johnsrude I, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. Cerebral asymmetry and the effects of sex and handedness on brain structure: a voxel-based morphometric analysis of 465 normal adult human brains. Neuroimage. 2001; 14: 685–700.
  • 30
    Ashburner J, Neelin P, Collins DL, Evans A, Friston K. Incorporating prior knowledge into image registration. Neuroimage. Nov 1997; 6: 344–352.
  • 31
    Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999; 7: 254–266.
    Direct Link:
  • 32
    Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant voxels in images of cerebral activation. Hum Brain Mapp. 1996; 4: 58–73.
    Direct Link:
  • 33
    Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage. Dec 1996; 4(3 pt 1): 223–235.
  • 34
    Brett M, Johnsrude IS, Owen AM. The problem of functional localization in the human brain. Nat Rev Neurosci. 2002; 3: 243–249.
  • 35
    Petrides M. Mapping prefrontal cortical systems for the control of cognition. In: TogaAW, MazziottaJC, eds. Brain mapping: the systems. 1st ed. New York: Academic Press; 2000: 159–176.
  • 36
    Witter MP, Wouterlood F. Parahippocampal region: organization and role in cognitive functions. New York and London: Oxford University Press; 2002.
  • 37
    Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. Brain. 2006; 129(pt 3): 564–583.
View Full Article (HTML) Get PDF (417K)